Cargando…
Targeting the NANOG/HDAC1 axis reverses resistance to PD-1 blockade by reinvigorating the antitumor immunity cycle
Immune checkpoint blockade (ICB) therapy has shifted the paradigm for cancer treatment. However, the majority of patients lack effective responses because of the emergence of immune-refractory tumors that disrupt the amplification of antitumor immunity. Therefore, the identification of clinically av...
Autores principales: | Oh, Se Jin, Lee, Hyo-Jung, Song, Kwon-Ho, Kim, Suyeon, Cho, Eunho, Lee, Jaeyoon, Bosenberg, Marcus W., Kim, Tae Woo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920337/ https://www.ncbi.nlm.nih.gov/pubmed/35104240 http://dx.doi.org/10.1172/JCI147908 |
Ejemplares similares
-
Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis
por: Oh, Se Jin, et al.
Publicado: (2020) -
Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade
por: Freeman, Gordon J., et al.
Publicado: (2006) -
PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells
por: Viramontes, Karla M., et al.
Publicado: (2022) -
Distinct Dynamics of Migratory Response to PD-1 and CTLA-4 Blockade Reveals New Mechanistic Insights for Potential T-Cell Reinvigoration following Immune Checkpoint Blockade
por: Safaeifard, Fateme, et al.
Publicado: (2022) -
NANOG confers resistance to complement-dependent cytotoxicity in immune-edited tumor cells through up-regulating CD59
por: Son, Sung Wook, et al.
Publicado: (2022)